17 recruiting, 13 completed, 4 unknown, 2 active not recruiting. 22 Phase 2, 13 Phase 1, 4 Not applicable, 2 Early Phase 1.
Follow Plasma Cell Leukemia: new trials by email Literature Review of Plasma Cell Leukemia trials Research Report on Plasma Cell Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-07 |
| Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma Isatuximab - Multiple Myeloma, Plasma Cell Leukemia | Phase 2 | Recruiting | University of Utah | 40 | 2025-10-09 | 2026-09-11 |
| A Study of CT0596 in Plasma Cell Leukemia CAR-T cells Infusion chimeric antigen receptor T cells - Plasma Cell Leukemia | Early Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 27 | 2025-06-25 | 2025-08-01 |
| Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM BCMA CART - Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions, Cytogenetics Ultra High Risk | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2025-03-03 | 2025-08-07 |
| The Norwegian Immunotherapy in Multiple Myeloma Study Teclistamab, Elranatamab, Ciltacabtagene Autoleucel - Myeloma Multiple, Plasma Cell Leukemia | Recruiting | St. Olavs Hospital | 400 | 2025-01-15 | 2026-07-20 | |
| An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia CAR-T（RD140 injection） - Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia | Phase 1 | Not yet recruiting | Peking University People's Hospital | 12 | 2024-10-25 | 2024-10-23 |
| A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia anti-BCMA CAR-T, VRD-based regimen - Plasma Cell Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2023-08-14 | 2025-08-03 |
| Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Itacitinib - Leukemia, Acute, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 32 | 2023-07-06 | 2026-10-07 |
| To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL Human BCMA targeted CAR-NK cells injection - Multiple Myeloma, Plasma Cell Leukemia | Early Phase 1 | Recruiting | Hrain Biotechnology Co., Ltd. | 18 | 2023-07-04 | 2023-09-21 |
| A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia anti-BCMA CAR-T - Plasma Cell Leukemia | Phase 2 | Active not recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2023-05-23 | 2026-07-01 |
| Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant Budesonide EC, Placebo - Multiple Myeloma, Plasma Cell Leukemia | Phase 2 | Recruiting | University of Utah | 120 | 2023-05-03 | 2026-06-05 |
| Allo HSCT Using RIC and PTCy for Hematological Diseases Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 56 | 2023-05-01 | 2026-07-06 |
| CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia CT0594CP - Multiple Myeloma, Plasma Cell Leukemia | Not applicable | Unknown | The First Affiliated Hospital of Soochow University | 6 | 2023-04-12 | 2023-04-20 |
| A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia CAR-GPRC5D - Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia | Phase 1 | Recruiting | Nanjing IASO Biotechnology Co., Ltd. | 12 | 2023-03-30 | 2025-05-20 |
| European Myeloma Network (EMN) Sample Project storage of biological samples - Multiple Myeloma, Smoldering Multiple Myeloma | Recruiting | European Myeloma Network B.V. | 6000 | 2022-12-21 | 2025-12-03 | |
| Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate - B-Cell Lymphoma, Myelodysplastic Syndromes (MDS) | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 80 | 2022-11-01 | 2026-08-07 |
| A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia CAR-T (CAR-GPRC5D) - Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia | Phase 1 | Recruiting | Chunrui Li | 18 | 2022-03-17 | 2025-06-11 |
| Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation Daratumumab - Plasma Cell Leukemia | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 29 | 2021-10-01 | 2021-09-23 |
| A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH No intervention - Multiple Myeloma, Amyloidosis | Recruiting | Peking University First Hospital | 2000 | 2021-07-01 | 2026-09-16 | |
| Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry Multiple Myeloma, Amyloidosis | Recruiting | University of Alabama at Birmingham | 5000 | 2020-07-21 | 2025-12-08 |
Showing 20 of 43. Sign in to see all of them.
Leukemia, Plasma Cell (43) · Multiple Myeloma (35) · Leukemia, Lymphocytic, Chronic, B-Cell (8) · Leukemia, Myeloid, Acute (7) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Leukemia, Prolymphocytic (6) · Myelodysplastic Syndromes (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Burkitt Lymphoma (5) · Lymphoma, B-Cell, Marginal Zone (5) · Lymphoma, Follicular (5) · Lymphoma, Mantle-Cell (5) · Myeloproliferative Disorders (5) · Primary Myelofibrosis (5) · Amyloidosis (4)
Hemic and Lymphatic Diseases (43) · Immune System Diseases (43) · Immunoproliferative Disorders (43) · Lymphoproliferative Disorders (43) · Neoplasms (43) · Neoplasms by Histologic Type (43) · Hematologic Diseases (41) · Leukemia (41) · Neoplasms, Plasma Cell (40) · Cardiovascular Diseases (35) · Hemorrhagic Disorders (35) · Hemostatic Disorders (35) · Vascular Diseases (35) · Blood Protein Disorders (34) · Paraproteinemias (33)
Dexamethasone (8) · Melphalan (8) · fludarabine (8) · fludarabine phosphate (8) · Cyclophosphamide (7) · Peripheral Blood Stem Cell Transplantation (6) · Whole-Body Irradiation (6) · Bortezomib (5) · Lenalidomide (5) · Mycophenolic Acid (5) · Tacrolimus (5) · Calcium Dobesilate (4) · Sirolimus (3) · Stem Cell Transplantation (3) · auricularum (3)
Institute of Hematology & Blood Diseases Hospital, China (5) · Masonic Cancer Center, University of Minnesota (5) · M.D. Anderson Cancer Center (4) · City of Hope Medical Center (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · University of Utah (2) · AbbVie (1) · Assistance Publique - Hôpitaux de Paris (1) · Chunrui Li (1) · Clinical Service, China (1) · European Myeloma Network B.V. (1) · Fred Hutchinson Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hrain Biotechnology Co., Ltd. (1) · Mayo Clinic (1)
United States (27) · China (11) · Australia (1) · Austria (1) · Belgium (1) · Czechia (1) · Greece (1) · Ireland (1) · Italy (1) · Norway (1) · Portugal (1) · Serbia (1) · South Africa (1) · Switzerland (1)
Amrita Krishnan (1) · Amy E DeZern, MD (1) · Attaphol Pawarode, MD (1) · Bruno Royer, MD (1) · Chunrui Li (1) · Claudio Brunstein, MD (1) · Danai Dima, MD (1) · David Marin, MD (1) · Dehui Zou (1) · Douglas W Sborov (1) · Erica Warlick, MD (1) · Firoozeh Sahebi, MD (1) · Ghulam Rehman Mohy-ud-din, MBBS (1) · Ghulam Rehman Mohyuddin, MBBS (1)
PMID 41118600, PMID 28817190, PMID 41144785
2019 (1), P01CA015396 (1), P30CA015704 (1), P30CA016672 (1), U10CA180821 (1)